Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

Phase 2 Not yet recruiting 36 enrolled Keros Therapeutics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.

Timeline

Start: 2026-09-14
Primary completion: 2029-07-17
Completion: 2029-08-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KER-065	Unknown	—	Subcutaneous

Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

Summary

Timeline

Drugs

Indications